Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats

References

• Beermann B. (1973). Value of plasma-digoxin estimation. Lancet 1:375
   Google Scholar
• Chi YH, Lee H, Paik SH, et al. (2011). Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects. Am J Cardiovasc Drugs 11:335–46
   PubMed Web of Science ®Google Scholar
• Christ DD, Wong PC, Wong YN, et al. (1994). The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog. J Pharmacol Exp Ther 268:1199–205
   PubMed Web of Science ®Google Scholar
• Davi H, Tronquet C, Miscoria G, et al. (2000). Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques. Drug Metab Dispos 28:79–88
   PubMed Web of Science ®Google Scholar
• Deguchi T, Watanabe N, Kurihara A, et al. (2011). Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach. Drug Metab Dispos 39:820–9
   PubMed Web of Science ®Google Scholar
• Ieiri I, Nishimura C, Maeda K, et al. (2011). Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genom 21:495–505
   PubMed Web of Science ®Google Scholar
• Jeon H, Lim KS, Shin KH, et al. (2012). Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers. J Cardiovasc Pharmacol 59:84–91
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee JH, Paik SH, et al. (2012a). Fimasartan, a novel angiotensin II receptor antagonist. Arch Pharm Res 35:1123–6
   PubMed Web of Science ®Google Scholar
• Kim TW, Yoo BW, Lee JK, et al. (2012b). Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. Bioorg Med Chem Lett 22:1649–54
   PubMed Web of Science ®Google Scholar
• Lane A, Engmann E, Bryson S, et al. (2005a). Single dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Pharmacol Ther 77:P59
   Web of Science ®Google Scholar
• Lane A, Kleinermanns D, Bryson S, et al. (2005b). Multiple dose pharmacokinetics (PK) and pharmacodynamics (PD) of BR-A-657, an angiotensin II (AII) antagonist. Clin Pharmacol Ther 77:P58
   Google Scholar
• Lee HW, Lim MS, Seong SJ, et al. (2011). Effect of age on the pharmacokinetics of fimasartan (BR-A-657). Expert Opin Drug Metab Toxicol 7:1337–44
   PubMed Web of Science ®Google Scholar
• Lee J, Han S, Jeon S, et al. (2013). Pharmacokinetic–pharmacodynamic model of fimasartan applied to predict the influence of a high fat diet on its blood pressure-lowering effect in healthy subjects. Eur J Clin Pharmacol 69:11–20
   Google Scholar
• Lee SE, Kim YJ, Lee HY, et al., Investigators. (2012). Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension. Clin Ther 34:552–68, 568e1–9
   Google Scholar
• Miura M, Satoh S, Inoue K, et al. (2009). Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clin Chim Acta 399:83–7
   PubMed Web of Science ®Google Scholar
• Park JB, Sung KC, Kang SM, Cho EJ. (2013). Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study. Am J Cardiovasc Drugs 13:47–56
   PubMed Web of Science ®Google Scholar
• Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. (2002). Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751–90
   PubMed Web of Science ®Google Scholar
• Shin BS, Kim TH, Paik SH, et al. (2011). Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography–tandem mass spectrometry. Biomed Chromatogr 25:1208–14
   Google Scholar
• Veng Pedersen P. (1981). Pharmacokinetic analysis by linear system approach I: cimetidine bioavailability and second peak phenomenon. J Pharm Sci 70:32–8
   Google Scholar
• Yi S, Kim JW, Kim TE, et al. (2011a). Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers. Int J Clin Pharmacol Ther 49:321–7
   PubMed Web of Science ®Google Scholar
• Yi S, Kim TE, Yoon SH, et al. (2011b). Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers. J Cardiovasc Pharmacol 57:682–9
   PubMed Web of Science ®Google Scholar
• Zhou H. (2003). Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 43:211–27
   PubMed Web of Science ®Google Scholar